| Current Price | $0.48 | Mkt Cap | $71.1M |
|---|---|---|---|
| Open | $0.48 | P/E Ratio | -0.60 |
| Prev. Close | $0.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.46 - $0.50 | Volume | 542,476 |
| 52-Wk Range | $0.45 - $2.55 | Avg. Daily Vol. | 879,470 |
| Current Price | $0.48 | Mkt Cap | $71.1M |
|---|---|---|---|
| Open | $0.48 | P/E Ratio | -0.60 |
| Prev. Close | $0.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.46 - $0.50 | Volume | 542,476 |
| 52-Wk Range | $0.45 - $2.55 | Avg. Daily Vol. | 879,470 |
The best Bull and Bear pitches based on recency and number of recommendations.
Affimed is another leap of faith stock for me, in that I made my initial trades in the stock purely on Portefeuille's instructions and currently have 1500 shares with a cost basis of 6. I finally got around to reviewing the stock today and so far I'm… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about AFMD.
Recs
zzlangerhans
(99.37)
Submitted: 1/15/2015 1:20:17 AM :
Start Price:
$6.01
NASDAQ:AFMD Score:
-207.62
Affimed is another leap of faith stock for me, in that I made my initial trades in the stock purely on Portefeuille's instructions and currently have 1500 shares with a cost basis of 6. I finally got around to reviewing the stock today and so far I'm pretty happy with the position. Affimed is developing bispecific antibodies, which was a very productive platform for Micromet before they were bought out by Amgen for a significant premium in 2012. Affimed's lead compound, AFM13 for relapsed/refractory Hodgkin's and CTCL, should begin a phase IIa trial in the near future.
Affimed hasn't garnered much love since their 2014 IPO, actually closing below their IPO price on the first day of trading. I can't remember the last time I saw that happen for an oncology biotech IPO. Perhaps there's something to the market's skepticism - I haven't been a very good judge of cheap bios with proprietary platforms recently. On the other hand, Affimed's base in Heidelberg makes them well-suited to be followed by Portefeuille. European-based biopharmas are often neglected by US based traders, even when they trade on US exchanges. There's clearly much more to be learned about Affimed but zzporte is already in the green thanks to a couple of timely trades so for now I'm happy to be along for the ride.
Find the members with the highest scoring picks in AFMD.
NobleOrSomeBull (99.76) Score: +226.09
The Score Leader is the player with the highest score across all their picks in AFMD.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| BobbyCyclone | 27.25 | 3/10/2015 |
|
5Y | $6.06 | -92.14% | +109.35% | +201.49 | 0 Comment | |
| NobleOrSomeBull | 99.76 | 7/6/2016 |
|
5Y | $2.74 | -82.62% | +106.08% | +188.70 | 0 Comment | |
| AtlanticoClub | 87.82 | 7/24/2020 |
|
5Y | $4.12 | -88.44% | +34.60% | +123.04 | 0 Comment | |
| Playa17 | < 20 | 10/5/2022 |
|
5Y | $2.13 | -77.64% | +15.53% | -93.17 | 0 Comment | |
| Reallynow222 | 88.97 | 5/14/2021 |
|
5Y | $9.00 | -94.71% | +4.16% | -98.87 | 0 Comment | |
| TruffelPig | < 20 | 5/11/2021 |
|
5Y | $8.95 | -94.68% | +4.43% | -99.11 | 0 Comment | |
| soypollo | 29.61 | 2/8/2021 |
|
5Y | $5.76 | -91.73% | +10.82% | -102.55 | 0 Comment | |
|
biznessdoc | 58.84 | 11/27/2020 |
|
5Y | $5.17 | -90.79% | +18.57% | -109.35 | 0 Comment |
| ttkam20 | < 20 | 7/17/2020 |
|
5Y | $4.27 | -88.85% | +34.03% | -122.88 | 0 Comment | |
| NextGenStock20 | < 20 | 7/13/2020 |
|
5Y | $4.51 | -89.44% | +34.74% | -124.18 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
